Anixa biosciences inc (ANIX)
CashFlow / Yearly
Oct'19Oct'18Oct'17Oct'16Oct'15Oct'14Oct'13Oct'12Oct'11Oct'10
Accounts payable and accrued expenses

-

-

-

-

-868

-27

641

174

10

53

Royalties and contingent legal fees payable

-

-

-

-213

-347

352

207

0

-

-

Deferred revenue

-

-

-

-

-

-1,187

0

-940

2,127

-

Cash flows from operating activities:
Net loss

-11,818

-14,243

-5,008

-5,016

-

-

-

-

-

-

Net loss

-

-

-

-

-1,379

-9,606

-10,080

-4,252

-7,378

-5,175

Stock option compensation to employees and directors

3,560

5,717

1,219

873

2,676

3,149

-

-

742

-

Stock options and warrants issued to consultants

198

318

3

-

-

-

-

-

-

-

Restricted stock award compensation to employee pursuant to stock incentive plan

1,954

2,859

454

-

-

-

-

-

-

-

Accretion of interest on patent acquisition obligations to interest expense

-

-

228

-519

-451

385

-

-

-

-

Common stock issued to consultants

-

-

-

31

46

84

-304

-

-

-

Depreciation of property and equipment

-

-

43

33

12

-

-

-

7

-

Depreciation of property and equipment

47

18

-

-

-

-

-

-

-

8

Stock option compensation to employees

-

-

-

-

-

-

2,693

-

1,819

-

Stock option compensation to consultants

-

-

-

-

-

-

1,105

-

-

-

Common stock issued to consultants

-

15

32

-

-

-

-

-

-

-

Common stock issued to consultants

-

-

-

-

-

-

-

75

-

-

Common stock issued to pay interest on convertible debentures

-

-

-

-

-

-

-

0

-

-

Amortization of patents

418

325

325

325

325

314

0

-

-

-

Loss on disposal of property and equipment

-

-

-45

0

-10

-

-

-

-

-

Impairment in carrying amount of patent asset

418

582

-

-

-

-

-

-

-

-

Accrued interest reversed on conversion of convertible debenture

-

-

-

-

-

173

0

-

-

-

Amortized interest on patent acquisition obligations to interest expense

-

-

-

-

-

-

0

-

-

-

Amortization of convertible debenture discount charge to interest expense

-

-

-

-

-

634

991

0

-

-

Impairment in value of investment in Videocon Industries Limited GDRs

-

-

-

-

-

-62

-1,184

0

-1,785

-

Accrued interest on secured debenture

-

-

-

-

-

61

98

-

-

-

Change in value of derivative liability

-

-

-

-

-

-592

475

0

-

-

Gain on extinguishment of patent acquisition obligation (Note 4)

-

-

1,547

0

-

-2,699

-343

0

-

-

Issuance of noncontrolling interest in Certainty Therapeutics, Inc. expensed as a license fee

-

64

-

-

-

-

-

-

-

-

Non-cash patent acquisition

-

-

-

-

-

3,036

0

-

-

-

Common stock issued to acquire patent license

-

-

-

11

-

185

42

-

-

-

Loss on acquisition of common stock and warrants to purchase common stock

-

-

-

-

-101

-

-

-

-

-

Common stock issued

-

-

-

-

-

-

-

75

-

-

Common stock issued to acquire patent license

-

-

-

-

-

-16

-42

0

-

-

Change in operating assets and liabilities:
Impairment in value of investment in Volga-Svet Ltd.

-

-

-

-

-

-

-

127

-

-

Gain on sale of Digital Info Security Co., Inc. common stock

-

-

-

-

-

-

-

-

-30

4

Other

-

-

-

-

-

-38

-9

7

-3

-43

Accounts receivable

-

-

-

-

-400

225

175

0

-

-

Receivables

-271

258

-

-

-

-

-

-

-

-

Prepaid expenses and other current assets

9

48

12

35

65

-100

78

13

45

-10

Accounts payable

3

101

107

-1

-

-

-

-

-

-

Accrued expenses

212

273

313

89

-

-

-

-

-

-

Net cash used in operating activities

-4,741

-4,273

-3,796

-3,381

1,363

-2,379

-3,186

-3,140

-716

-2,405

Cash flows from investing activities:
Disbursements to acquire short-term investments in certificates of deposit

3,850

4,250

5,501

1,900

2,900

5,200

250

1,200

3,947

749

Proceeds from maturities of short-term investments in certificates of deposit

3,500

5,750

2,751

3,550

3,000

2,700

750

2,948

1,699

1,500

Proceeds from sale of Digital Info Security Co. Inc. common stock

-

-

-

-

-

-

-

-

118

51

Proceeds from sale of property and equipment

-

-

45

0

-

-

-

-

-

-

Purchase of property and equipment

175

38

30

146

54

6

-

-

9

2

Other

-

-

-

-

-

-

0

0

-

-

Net cash (used in) provided by investing activities

-525

1,461

-2,735

1,503

45

-2,506

499

1,747

-2,138

799

Cash flows from financing activities:
Proceeds from sale of common stock in shareholder rights offering

-

-

4,203

0

-

-

-

-

-

-

Proceeds from sale of common stock in registered direct offering

-

-

3,211

-

-

-

-

-

-

-

Proceeds from issuance of convertible debentures

-

-

-

-

-

3,500

1,765

750

-

-

Proceeds from sale of common stock in registered direct offering

-

-

-

0

-

-

-

-

-

-

Net proceeds from sale of common stock in at-the-market offering

5,527

2,470

3,460

0

-

3,673

1,050

0

-

-

Proceeds from sale of common stock pursuant to employee stock purchase plan

39

-

-

-

-

-

-

-

-

-

Proceeds from settlement of shareholder derivative complaint

14

-

-

-

-

-

-

-

-

-

Redemption of convertible preferred stock

-

-

500

0

-

-

-

-

-

-

Payments made on secured debenture

-

-

3,000

0

-

-

-

-

-

-

Proceeds from exercise of warrants to purchase common stock

-

-

-

-

-

300

380

0

-

-

Proceeds from private placement

-

-

-

-

-

-

-

-

1,250

-

Proceeds from exercise of stock options

122

58

7

33

44

75

25

208

1,284

1,249

Royalty payment applied to patent acquisition obligation

-

-

-

36

-

-

-

-

-

-

Payments to acquire 92,232 shares of common stock and cancellation of warrants to purchase 16,000 shares of common stock

-

-

-

-

445

-

-

-

-

-

Payments to redeem convertible securities

-

-

-

-

-

200

0

-

-

-

Proceeds received on sale of common stock held by ZQX Advisors, LLC

-

-

-

-

-

-

-

0

-

-

Net cash provided by financing activities

5,702

2,528

7,382

-2

-400

7,349

3,245

958

2,534

1,249

Net (decrease) increase in cash and cash equivalents

435

-283

-

-

-

-

-

-

-

-

Net increase in cash and cash equivalents

-

-

851

-1,880

1,007

2,463

558

-434

-320

-357

Common stock issued upon conversion of debentures

-

-

-

-

-

2,735

1,353

-

-

-

Supplemental disclosure of non-cash investing and financing activities:
Payments to suppliers, employees and consultants

-

-

-

-

-

-

-

3,164

-3,280

3,209

Cash received from patent monetization and patent assertion

-

-

-

-

-

-

-

7

-

-

Dividends and interest received

-

-

-

-

-

-

-

16

-

-

Cash received from sales of products and services

-

-

-

-

-

-

-

-

130

126

Cash received from display technology license fee, net of taxes

-

-

-

-

-

-

-

-

2,400

600

Dividend received

-

-

-

-

-

-

-

-

33

68

Cash proceeds from interest income

55

12

-

-

-

-

-

-

-

8

Supplemental disclosure of non-cash investing activity:
Disposal of fully depreciated property and equipment

-6

-

-

-

-

-

-

-

-

-

Supplemental disclosure of non-cash financing activity:
Note receivable issued for settlement of shareholder derivative complaint

31

-

-

-

-

-

-

-

-

-

Cash payments for interest

-

-

272

-

-

-

-

-

-

-

Cash payments for interest

-

-

-

0

-

-

-

-

-

-

Redemption of Series A convertible preferred stock into secured debenture (Note 5)

-

-

3,000

0

-

-

-

-

-

-

Fair value of debenture embedded conversion feature, at issuance

-

-

-

-

-

1,570

1,180

-

-

-

Relative fair value of convertible debenture warrant, at issuance

-

-

-

-

-

513

214

-

-

-

Non-cash acquisition of 20,000,000 shares of common stock

-

-

-

-

-

4,134

0

-

-

-

Common stock issued to pay patent acquisition obligation (Note 4)

-

-

2,852

0

-

5,229

603

-

-

-

Cancellation of loan receivable from former affiliate

-

-

-

-

-

-5,000

0

-

-

-

Cancellation of loan payable to former affiliate

-

-

-

-

-

5,000

0

-

-

-

Net cash used in operating activities

-4,741

-4,273

-3,796

-3,381

-

-

-

-3,140

-716

-2,405